Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding

Shared vision for improving patient and staff safety and minimizing waste of pharmaceuticals.

Frisco, TX - Nov. 12th, 2007 - The convergence of a world-class sales and service organization and a manufacturing organization will allow both companies to drive new growth opportunities and ultimately transform the way cancer-fighting drugs are prepared and administered. By combining Primus Innovations, Inc. solutions, sales, and services with Health Robotics engineering, software and robotic chemotherapy compounding technology “CytoCareTM”, will enable a new standard of precision, accuracy, safety, and price efficiencies in chemotherapy admixtures.

Jack Risenhoover, Health Robotics Managing Principal, described the trampoline effect of the combination as a “powerful tool in the battle against cancer. We are particularly pleased that Primus Innovations has selected CytoCare as its exclusive solution for chemotherapy compounding for hospitals and outpatient infusion centers. Primus’ experience in outsourcing will be a significant advantage for CytoCare customers.”

Steve Bohannon, Primus Innovations, Inc. CEO and President, said “Health Robotics has designed an incredible product that tilts scales in the battle against cancer. In CytoCare we have a rare triple win: more accurate infusions for patients, a far safer environment for pharmacists and technicians and better economics, and regulatory compliance for hospitals, clinics and physicians. We are incredibly pleased to be the exclusive distributor and service provider for CytoCare in North America.”

CytoCare provides unparalleled benefits for patients, staff and pharmacists. The sterile robotic environment minimizes manual interaction and the associated risk of contamination. It supports patient-specific dosing, by using the patient’s unique physical profi le. Thus the medication regimen is tailored, and accurate with swifter, more effective results.

Dosing accuracy is further enhanced with automation-compounded safety checks, increasing patient protection from medication errors. Over 475 discrete information details are automatically tracked as part of the permanent electronic medical record. To achieve USP 797 and other regulatory compliance, CytoCare provides an audit trail for record keeping purposes. CytoCare generates significant, immediate savings by effi ciently using partial drug vials with automated time/date stamps and beyond use expiration alerts based on user defined protocols.


For more information on CytoCare, contact Primus Innovations at (972) 439-6821 or email us at primusinnovations@primusinnovations.com

About Primus Innovations, Inc:
Primus Innovations, Inc., located in Frisco, Texas, is the pre-eminent provider of automation,
technology and services to the Oncology Industry. Primus is a strategic business partner to
its customers, offering a full suite of professional services encompassing all of the elements
of support and outsourcing that our customers may require allowing them to focus on
their core business. Primus also provides flexible financing programs which are designed
to meet their customers’ economic requirements. For more information, please visit:
www.primusinnovations.com

About HealthRobotics:
Health Robotics is the worldwide leader in patient specific, robotic chemotherapy
admixtures. Its advanced technology and innovative engineering enhances sterility, delivers
accurate doses for patients, and helps protect clinicians from exposure to cytotoxic agents
that can occur during manual compounding. www.healthrobotics.net